William D Chey

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
    W D Chey
    GI Physiology Laboratory, University of Michigan Health System, Ann Arbor, 48109 0362, USA
    Aliment Pharmacol Ther 35:587-99. 2012
  2. ncbi Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy
    W D Chey
    Department of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Aliment Pharmacol Ther 19:1-8. 2004
  3. ncbi Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea
    William D Chey
    University of Michigan, Division of Gastroenterology, Ann Arbor, MI, USA
    Expert Opin Investig Drugs 14:185-93. 2005
  4. ncbi Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey
    W D Chey
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Aliment Pharmacol Ther 23:655-68. 2006
  5. ncbi Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment
    William D Chey
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Curr Gastroenterol Rep 8:273-81. 2006
  6. ncbi Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?
    William D Chey
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Dig Dis Sci 55:3415-22. 2010
  7. ncbi Treatment patterns and symptom control in patients with GERD: US community-based survey
    William D Chey
    University of Michigan Health System, Ann Arbor, MI 48109 0362, USA
    Curr Med Res Opin 25:1869-78. 2009
  8. ncbi Tegaserod in the treatment of irritable bowel syndrome with constipation
    Richard Saad
    GI Physiology Laboratory, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, USA
    Womens Health (Lond Engl) 2:29-42. 2006
  9. ncbi Review article: tegaserod -- the global experience
    W D Chey
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Aliment Pharmacol Ther 20:15-9. 2004
  10. ncbi Accurate diagnosis of Helicobacter pylori. 14C-urea breath test
    W D Chey
    University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Gastroenterol Clin North Am 29:895-902. 2000

Collaborators

Detail Information

Publications76

  1. ncbi Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
    W D Chey
    GI Physiology Laboratory, University of Michigan Health System, Ann Arbor, 48109 0362, USA
    Aliment Pharmacol Ther 35:587-99. 2012
    ..Irritable bowel syndrome with constipation (IBS-C) significantly decreases quality of life and the ability to perform daily living activities...
  2. ncbi Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy
    W D Chey
    Department of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Aliment Pharmacol Ther 19:1-8. 2004
    ..The test-and-treat approach would receive increased enthusiasm if H. pylori cure is shown to prevent development of gastric cancer in non-ulcer dyspepsia patients in a large Western trial...
  3. ncbi Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea
    William D Chey
    University of Michigan, Division of Gastroenterology, Ann Arbor, MI, USA
    Expert Opin Investig Drugs 14:185-93. 2005
    ..A detailed risk management plan and post-marketing surveillance programme will be required should this drug become available for the treatment of patients with IBS-D...
  4. ncbi Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey
    W D Chey
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Aliment Pharmacol Ther 23:655-68. 2006
    ..To assess primary care physician perceptions of non-steroidal anti-inflammatory drug (NSAID) and aspirin-associated toxicity...
  5. ncbi Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment
    William D Chey
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Curr Gastroenterol Rep 8:273-81. 2006
    ..This article reviews the accumulating body of evidence supporting the importance of neuromuscular dysfunction as a central cause of IBS symptoms and provides a rationale for the discussion of current and future drug development...
  6. ncbi Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?
    William D Chey
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Dig Dis Sci 55:3415-22. 2010
    ..Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD)...
  7. ncbi Treatment patterns and symptom control in patients with GERD: US community-based survey
    William D Chey
    University of Michigan Health System, Ann Arbor, MI 48109 0362, USA
    Curr Med Res Opin 25:1869-78. 2009
    ..Proton pump inhibitors (PPIs) are the most commonly used pharmacological treatment for gastroesophageal reflux disease (GERD)...
  8. ncbi Tegaserod in the treatment of irritable bowel syndrome with constipation
    Richard Saad
    GI Physiology Laboratory, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, USA
    Womens Health (Lond Engl) 2:29-42. 2006
    ....
  9. ncbi Review article: tegaserod -- the global experience
    W D Chey
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Aliment Pharmacol Ther 20:15-9. 2004
    ....
  10. ncbi Accurate diagnosis of Helicobacter pylori. 14C-urea breath test
    W D Chey
    University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Gastroenterol Clin North Am 29:895-902. 2000
    ..As such, the 14C-urea breath test provides an attractive, nonendoscopic means of identifying active H. pylori infection...
  11. ncbi Gastric emptying characteristics of a novel (13)C-octanoate-labeled muffin meal
    W D Chey
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    J Clin Gastroenterol 32:394-9. 2001
    ..Determine the gastric emptying characteristics of a novel, 350-kcal test meal consisting of two muffins, using scintigraphy and the 13C-octanoate breath test (OBT)...
  12. ncbi Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice
    W D Chey
    Divisions of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Arch Intern Med 161:2129-32. 2001
    ..Clinical guidelines support a noninvasive Helicobacter pylori "test-and-treat" strategy for individuals with uncomplicated dyspepsia. However, consensus is lacking regarding the preferred noninvasive testing method...
  13. ncbi Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS
    William L Hasler
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Physiol Gastrointest Liver Physiol 297:G1107-14. 2009
    ..Constipated patients with normal or moderately delayed transit show increased motor activity that is partly explained by IBS. These findings emphasize differential effects on transit and motility in different constipation subtypes...
  14. ncbi Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls
    Richard J Saad
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 105:403-11. 2010
    ..The aim of this study was to assess the correlation between stool characteristics (form and frequency) and gut transit in constipated and healthy adults...
  15. ncbi Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey
    William D Chey
    University of Michigan Health System, Ann Arbor, Michigan 49109-0362, USA
    Am J Gastroenterol 100:1237-42. 2005
    ..CONCLUSIONS: Our survey has identified a number of areas of controversy and confusion related to the management of GERD. We hope that our findings can assist in the development of educational materials on GERD for PCPs...
  16. ncbi Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation
    Braden Kuo
    Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
    Dig Dis Sci 56:2928-38. 2011
    ..The prevalence of generalized transit delay and relation to symptoms in suspected gastroparesis, intestinal dysmotility, or slow transit constipation are unknown...
  17. ncbi The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial
    William D Chey
    Divison of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Gastroenterol 105:859-65. 2010
    ..This study compared the prevalence of structural colonic lesions in patients with suspected non-constipation-predominant IBS and healthy volunteers. We also determined the yield of rectosigmoid biopsies in patients with suspected IBS...
  18. ncbi Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability
    Jay Luther
    University of Michigan Medical Center, Ann Arbor, USA
    Am J Gastroenterol 105:65-73. 2010
    ..We performed a systematic review and meta-analysis to compare the efficacy and tolerability of these regimens as first-line treatment of H. pylori...
  19. ncbi A clinician's guide to salvage therapy for persistent Helicobacter pylori infection
    Jay Luther
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI 48109 5682, USA
    Hosp Pract (Minneap) 39:133-40. 2011
    ....
  20. ncbi Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Richard J Saad
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Am J Gastroenterol 101:488-96. 2006
    ..CONCLUSIONS: A 10-day course levofloxacin triple therapy is more effective and better tolerated than 7-day bismuth-based quadruple therapy in the treatment of persistent H. pylori infection...
  21. ncbi A clinician's guide to managing Helicobacter pylori infection
    Richard Saad
    University of Michigan Medical Center, Ann Arbor 48109, USA
    Cleve Clin J Med 72:109-10, 112-3, 117-8 passim. 2005
    ..Care must be used in deciding whom to test for H pylori infection, as a positive result mandates treatment, making broad-based screening impractical...
  22. ncbi Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis
    U Ladabaum
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, CA 94143 0538, USA
    Aliment Pharmacol Ther 16:1491-501. 2002
    ..The benefits of the Helicobacter pylori test-and-treat strategy are attributable largely to the cure of peptic ulcer disease while limiting the use of endoscopy...
  23. ncbi Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies
    William D Chey
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 0362, Ann Arbor, MI 48109 0362, USA
    Dig Dis Sci 55:684-97. 2010
    ..Functional dyspepsia (FD) is a chronic disorder that adversely affects health-related quality of life (HRQoL). Published information on its long-term management is minimal and treatment options are limited...
  24. ncbi A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation
    William D Chey
    Department of Medicine, University of Michigan Health System, Ann Arbor, 48109 5362, USA
    Am J Gastroenterol 106:1803-12. 2011
    ..We conducted an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase IIb study, which evaluated A3309 in patients with chronic idiopathic constipation (CIC)...
  25. ncbi Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation
    Richard Saad
    Division of Gastroenterology, Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Expert Rev Gastroenterol Hepatol 2:497-508. 2008
    ..There is no evidence of a rebound in constipation or IBS symptoms following cessation of lubiprostone. In general, lubiprostone is well tolerated, with the most common side effects including nausea, headache and diarrhea...
  26. ncbi Breath tests for gastrointestinal disease: the real deal or just a lot of hot air?
    Richard J Saad
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Gastroenterology 133:1763-6. 2007
  27. ncbi Advances in the management of irritable bowel syndrome
    Brooks D Cash
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Box 0362, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0352, USA
    Curr Gastroenterol Rep 5:468-75. 2003
    ..No single medication has proven to be universally effective, and multiple therapeutic approaches exist. Greater understanding of gastrointestinal neurophysiology has led to promising advances in medical and nonmedical approaches to IBS...
  28. ncbi Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome
    William D Chey
    University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 99:2195-203. 2004
    ..CONCLUSIONS: Long-term use of alosetron is effective and well-tolerated in women with chronic, diarrhea-predominant IBS, including those with more frequent urgency...
  29. ncbi Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial
    William D Chey
    University of Michigan Health System, Division of Internal Medicine, Ann Arbor, Michigan, USA
    Am J Gastroenterol 103:1217-25. 2008
    ..This study aimed to evaluate the efficacy and safety of the 5-HT(4) agonist tegaserod in women with IBS-Mixed and IBS with constipation (IBS-C)...
  30. ncbi Emerging pharmacological therapies for the irritable bowel syndrome
    Monthira Maneerattanaporn
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Gastroenterol Clin North Am 40:223-43. 2011
    ..This fact has important implications for the choices and efficacy of IBS treatment. This article reviews the IBS drugs that have reached phase II or III clinical trials...
  31. ncbi Endoscopy-negative reflux disease: concepts and clinical practice
    William D Chey
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0362, USA
    Am J Med 117:36S-43S. 2004
    ..In those with persistent heartburn symptoms, other structural or nonacid reflux etiologies for their symptoms should be explored...
  32. ncbi Review article: current and emerging therapies for functional dyspepsia
    R J Saad
    University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Aliment Pharmacol Ther 24:475-92. 2006
    ..A variety of emerging therapies are being developed for functional dyspepsia. Most of these therapies are intended to normalize pain perception and gastrointestinal motor and reflex function in this group of patients...
  33. ncbi Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication
    F Ahmed
    Division of Gastroenterology, Syracuse VA Medical Center, Syracuse, NY 10128, USA
    Aliment Pharmacol Ther 22:875-80. 2005
    ..The urea blood test (Ez-HBT) has been shown to compare favourably with the urea breath test in the diagnosis of active Helicobacter pylori infection...
  34. ncbi Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor
    W D Chey
    University of Michigan Health System, Ann Arbor, USA
    Am J Gastroenterol 96:1028-32. 2001
    ..These observations suggest that it may be possible to design a UBT protocol that will remain accurate in the face of PPI therapy...
  35. ncbi The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review
    Darren M Brenner
    Division of Gastroenterology, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Ann Arbor, Michigan, USA
    Am J Gastroenterol 104:1033-49; quiz 1050. 2009
    ..The aim of this study was to perform a systematic review of randomized controlled trials (RCTs) evaluating the efficacy, safety, and tolerability of probiotics in the treatment of IBS...
  36. ncbi Food: the forgotten factor in the irritable bowel syndrome
    Shanti Eswaran
    Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109 5362, USA
    Gastroenterol Clin North Am 40:141-62. 2011
    ..This article reviews the literature supporting a causal link between food and the symptoms of IBS as well as the evidence supporting dietary interventions as a means of managing IBS symptoms...
  37. ncbi Tegaserod and other serotonergic agents: what is the evidence?
    William D Chey
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Rev Gastroenterol Disord 3:S35-40. 2003
    ..The safety profile and restricted-use program for alosetron is also reviewed. This discussion is followed by a comprehensive review of the efficacy and safety data in support of tegaserod for women with constipation-predominant IBS...
  38. ncbi Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome
    J H Rubenstein
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Aliment Pharmacol Ther 26:443-52. 2007
    ..We hypothesized that such PPI non-responders have heightened oesophageal sensation, and that oesophageal hypersensitivity is associated with psychiatric features including somatization and anxiety...
  39. ncbi Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection
    W D Chey
    Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    Aliment Pharmacol Ther 12:1263-7. 1998
    ..We report a clinical trial which evaluated the effectiveness of triple therapy containing low- and high-dose azithromycin to treat Helicobacter pylori infection...
  40. ncbi Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers
    N Elnachef
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
    Aliment Pharmacol Ther 28:1249-58. 2008
    ..Our understanding of the benefits and risks of aspirin non steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective NSAIDs and gastro-protective agents (GPAs) continues to expand...
  41. ncbi An evidence-based approach to clinical practice guidelines: diagnosis and treatment of irritable bowel syndrome
    Philip Schoenfeld
    Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Clin Gastroenterol Hepatol 1:322-7. 2003
  42. ncbi Diagnosis of irritable bowel syndrome
    Brooks D Cash
    Division of Gastroenterology, Uniformed Services University of the Health Sciences, 8901 Wisconsin Avenue, Building 9, Bethesda, MD 20889, USA
    Gastroenterol Clin North Am 34:205-20, vi. 2005
    ..This article evaluates the diagnostic characteristics of various symptom-based criteria in routine clinical practice and reviews the data regarding the yield of the multiple commonly used diagnostic tests in patients with suspected IBS...
  43. ncbi Successful physical therapy for constipation related to puborectalis dyssynergia improves symptom severity and quality of life
    Christina Lewicky-Gaupp
    Division of Gynecology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0276, USA
    Dis Colon Rectum 51:1686-91. 2008
    ..This study evaluated symptom severity and quality of life in patients with puborectalis dyssynergia before and after physical therapy...
  44. ncbi Gastroesophageal reflux disease
    Colin W Howden
    Division of Gastroenterology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    J Fam Pract 52:240-7. 2003
    ..Unfortunately, the same survey found that most physicians recommend antireflux surgery for patients in whom medical therapy has failed...
  45. ncbi The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses
    Borko Nojkov
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48105, USA
    Am J Gastroenterol 105:842-7. 2010
    ....
  46. ncbi Testing for Helicobacter pylori in the clinical setting
    J M Lake
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
    Front Biosci 6:E129-36. 2001
    ..pylori-related disease. The potential advantages and disadvantages of various tests and the role of testing to confirm eradication after treatment for H. pylori is also discussed...
  47. ncbi Implications for treatment: pH, Helicobacter pylori or alternative approaches?
    W D Chey
    University of Michigan Medical Center, Ann Arbor, MI, USA
    Aliment Pharmacol Ther 21:17-8, 21-4. 2005
  48. ncbi The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis
    Stacy B Menees
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, 48109 5362, USA
    Am J Gastroenterol 107:28-35; quiz 36. 2012
    ..The objective of our study was to perform a meta-analysis and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients with IBS...
  49. ncbi American College of Gastroenterology guideline on the management of Helicobacter pylori infection
    William D Chey
    University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 102:1808-25. 2007
    ..Recent data suggest that a PPI, levofloxacin, and amoxicillin for 10 days is more effective and better tolerated than bismuth quadruple therapy for persistent H. pylori infection, though this needs to be validated in the United States...
  50. ncbi The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review
    Brooks D Cash
    Division of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Am J Gastroenterol 97:2812-9. 2002
    ..Based upon the increased pretest probability of celiac disease, routine performance of serological tests for celiac disease may be useful in this patient population, though additional study is needed in this area...
  51. ncbi Recent developments in the therapy of irritable bowel syndrome
    Richard J Saad
    Division of Gastroenterology, Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Expert Opin Investig Drugs 17:117-30. 2008
    ....
  52. ncbi Number of responses on a review of systems questionnaire predicts the diagnosis of functional gastrointestinal disorders
    William H Brown
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0362, USA
    J Clin Gastroenterol 36:222-7. 2003
    ..If seven positive symptoms is used as a threshold, the standardized review of systems questionnaire had a sensitivity of 92% and specificity of 80% in detecting patients with functional GI disorders...
  53. ncbi Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention
    William L Hasler
    Division of Gastroenterology, Univ of Michigan Health System, Ann Arbor, MI 48109, USA
    Am J Physiol Gastrointest Liver Physiol 294:G1384-91. 2008
    ..those with mild delays. Thus both etiology and degree of gastric stasis determine gastric acidity in gastroparesis...
  54. ncbi Successful treatment of common variable immunodeficiency disorder-associated diarrhea with budesonide: a case report
    Najwa Elnachef
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109 0362, USA
    Am J Gastroenterol 102:1322-5. 2007
    ..We report a patient with CVID and chronic diarrhea who significantly improved with budesonide...
  55. ncbi Agents that act luminally to treat diarrhoea and constipation
    Stacy Menees
    University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109 5362, USA
    Nat Rev Gastroenterol Hepatol 9:661-74. 2012
    ..As the physiological effects of luminally acting drugs are largely confined to the gastrointestinal tract, these agents are unlikely to cause adverse effects outside of the gastrointestinal tract...
  56. ncbi Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome
    Darren M Brenner
    Division of Gastroenterology, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Rev Gastroenterol Disord 9:7-15. 2009
    ..B. infantis 35624 appears safe and effective for the treatment of IBS...
  57. ncbi Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome
    William D Chey
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Gut Liver 5:253-66. 2011
    ....
  58. ncbi Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease
    Phyllissa Schmiedlin-Ren
    University of Michigan Medical School, Ann Arbor, 48109, USA
    Inflamm Bowel Dis 11:464-72. 2005
    ..These results suggest that targeting genes to inflamed intestine through the luminal route may be possible...
  59. ncbi Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women
    William D Chey
    University of Michigan, Ann Arbor, USA
    Am J Gastroenterol 97:2803-11. 2002
    ..These findings have important implications for clinical research in IBS patients and raise questions about whether the Rome II criteria are sensitive enough to be useful in clinical practice...
  60. ncbi The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease
    B Nojkov
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI, USA
    Aliment Pharmacol Ther 27:473-82. 2008
    ..A subset of patients with gastro-oesophageal reflux disease (GERD) does not achieve complete symptom resolution with proton pump inhibitor (PPI) therapy. The factors which affect response to PPI therapy in GERD patients remain unclear...
  61. ncbi Gastric distention correlates with activation of multiple cortical and subcortical regions
    U Ladabaum
    Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Gastroenterology 120:369-76. 2001
    ..However, the cerebral loci that process sensory information from the stomach are unknown. The aim of this study was to localize the human brain regions that are activated by gastric distention...
  62. ncbi Irritable bowel syndrome - an evidence-based approach to diagnosis
    B D Cash
    Division of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Aliment Pharmacol Ther 19:1235-45. 2004
    ..The presence of alarm features or persistent non-response to symptom-directed therapies should prompt a more detailed diagnostic evaluation dictated by the patient's predominant symptoms...
  63. ncbi Nausea and vomiting
    William L Hasler
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Gastroenterology 125:1860-7. 2003
  64. ncbi Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia
    Rajiv Bansal
    University of Michigan Medical Center, Division of Gastroenterology, Ann Arbor, Michigan 48109, USA
    J Clin Gastroenterol 36:209-14. 2003
    ..01). CONCLUSION: Initial therapy with Witzel dilatation is associated with better long-term outcome than a single injection of botox. Because of the risk of endoscopic perforation, botox remains a viable alternative to dilatation...
  65. ncbi Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation
    B D Cash
    Department of Gastroenterology, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda, MD, USA
    Aliment Pharmacol Ther 22:1047-60. 2005
    ....
  66. ncbi Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis
    J M Scheiman
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109, USA
    Am J Gastroenterol 96:2900-4. 2001
    ..The economic outcomes of EUS-, MRCP-, and ERCP-based diagnostic strategies were evaluated...
  67. ncbi Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial
    John F Johanson
    University of Illinois College of Medicine, Rockford, IL, USA
    Clin Gastroenterol Hepatol 2:796-805. 2004
    ..CONCLUSIONS: Over 12 weeks, tegaserod treatment produced significant improvements in chronic constipation symptoms and was also safe and well tolerated...
  68. ncbi Tegaserod does not alter fasting or meal-induced biliary tract motility
    Robert S Fisher
    Temple University Hospital, Philadelphia, USA
    Am J Gastroenterol 99:1342-9. 2004
    ....
  69. ncbi Functional bowel disorders
    George F Longstreth
    Kaiser Permanente Medical Care Program, San Diego, California 92120, USA
    Gastroenterology 130:1480-91. 2006
    ..Treatment of FBDs is based on an individualized evaluation, explanation, and reassurance. Alterations in diet, drug treatment aimed at predominant symptoms, and psychotherapy may be beneficial...
  70. ncbi Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data
    Lin Chang
    Center for Neurovisceral Sciences and Women's Health, Department of Medicine, UCLA and VA Greater Los Angeles Healthcare Center, California, USA
    Am J Gastroenterol 101:1069-79. 2006
    ..66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity...
  71. ncbi Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and Marquette University College of Health Sciences, Milwaukee, Wisconsin 53233, USA
    Am J Gastroenterol 103:1906-19. 2008
    ..Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD...
  72. ncbi Peptic ulcer disease in patients with chronic liver disease: looking beyond bugs and drugs
    Richard J Saad
    Gastrointest Endosc 62:357-9. 2005
  73. ncbi Design of treatment trials for functional gastrointestinal disorders
    E Jan Irvine
    Division of Gastroenterology, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 130:1538-51. 2006
    ..Trials should be registered in a public location, prior to initiation, and should be published even if the results are negative or inconclusive...
  74. ncbi Erosive esophagitis and NERD: Can we really classify patients with heartburn by endoscopic findings?
    William D Chey
    Clin Gastroenterol Hepatol 2:654-5. 2004
  75. ncbi Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways
    Einar S Björnsson
    Division of Gastroenterology, Department of Internal Medicine, Sahlgrenska University Hospital, S 41345 Gothenburg, Sweden
    Am J Physiol Gastrointest Liver Physiol 283:G400-7. 2002
    ..Thus abnormalities of neural reflex modulation of colonic motor function may play pathophysiological roles in slow-transit constipation...
  76. ncbi Clinical predictors of Barrett's esophagus length
    Ram Dickman
    The Neuro-Enteric Clinical Research Group, Southern Arizona VA Health Care System, Tucson, Arizona 85723-0001, USA
    Gastrointest Endosc 62:675-81. 2005
    ..05) were correlated with a shorter segment of BE. CONCLUSIONS: PPIs were correlated with shorter lengths of BE. In contrast, a longer hiatal hernia, any dysplasia, nonsmoking, or use of H2-RAs were correlated with a longer BE segment...